Abstract. Molecular targeting agents have become formidable anticancer weapons showing much promise against refractory tumors and functional peptides and are among the more desirable of these nanobio-tools. Intracellular delivery of multiple functional peptides forms the basis for a potent, non-invasive mode of delivery, providing distinctive therapeutic advantages. We examine the growth suppression efficiency of human renal cell carcinoma (RCC) by singlepeptide targeting. We simultaneously introduced p16 INK4a tumor suppressor peptides by Wr-t-mediated peptide delivery. Wr-t-mediated transport of p16
Introduction
renal cell carcinoma does not respond to chemotherapy or radiation therapy. In addition, unresectable recurrences or metastases have been treated only by cytokine therapy with INF or IL-2, which is not so effective, with a response rate of about 10-20% (1) (2) (3) (4) (5) (6) . Recently, tyrosine-kinase-targeting inhibitors (such as sorafenib, sunitinib, everolimus and temsirolimus), which are involved in the growth of cancer cells, and other signal transduction inhibitors have been developed for use in molecular targeted therapy and are beginning to be indicated for the treatment of metastatic renal cancer (7) (8) (9) (10) (11) (12) . Although these molecular targeting drugs are more effective than cytokine therapy, they have not provided satisfactory therapeutic results. Moreover, tyrosine-kinase inhibitors are associated with adverse reactions, including hand-foot syndrome and hypertension, while m-tOr inhibitors may cause adverse reactions such as interstitial pneumonia. therefore, there is a need for the continued development of more effective therapeutic agents associated with fewer adverse reactions for the treatment of renal cell carcinoma.
Protein transduction domains (PTDs) have recently been receiving attention as safe and effective tools in intracellular drug delivery systems. PTDs, being able to pass through the cell membrane of living cells, are considered useful for intracellular delivery of functional proteins or peptides targeting intracellular molecules, and many PTDs, including HIV-1 TAT, pAntp43-58 and polyarginine (R4-16), have been reported (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . In 1998, Nagahara et al produced a recombinant protein (TAT-p27 kip1 fusion protein), transduced it into cells, and induced G1 arrest and cell migration (16) . Kondo et al developed a system through which functional peptides and their transporter peptides were synthesized separately and attached to each other by mixing into a solution, and the A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system resulting complex was then used to deliver functional peptides to cells, instead of a system through which PTDs were directly bound to functional peptides or proteins. this transporter, wr-T, consisted of tryptophan-rich domains (serving as a cargo to attach functional peptides) fused with nine D-arginines serving as a PTD. They reported that the wr-T system provided higher delivery efficiency than Pep-1 (whose delivery efficiency is already reported) and achieved an antitumor effect by delivering antitumor peptides to leukemia, lymphoma and glioma cells (21) (22) (23) . In the present study, we delivered antitumor peptides to renal cell carcinoma cell lines using a similar system, and evaluated their antitumor effect. the antitumor peptides showed a strong antitumor effect on renal cell carcinoma without causing any abnormalities in normal tissues. This finding indicates that this therapy, associated with few adverse reactions, shows promise for clinical application in cancer treatment.
Materials and methods

Cells.
Human RCC lines sK-RC-1, 6, 7, 12, 14, 17, 33, 44, 52 and 59 (kindly provided by Dr lloyd j. old, msKCC), human cervical cancer cell line (Hela) and human bladder cancer cell line (575A) were maintained in RPmI-1640 containing 10% inactivated fetal bovine serum (Ibl, Gunma, japan), 100 u/ml of penicillin and 0.1 mg/ml of streptomycin, at 37˚C under an atmosphere of 5% CO 2 .
Peptide synthesis. All peptides including wr-T, r9-p16 minimal inhibitory sequence (mIs) were synthesized at bioGate Co. ltd. (Yamagata, japan). The identity of all peptides was confirmed by mass spectrometry. we prepared the HCl form of the peptides following high-performance liquid chromatography purification for in vitro and in vivo applications. peptide purity was >95%. the amino acid sequence of the Wr-t transporter is: KetWWetWWteWWteWsQ GPGrrrrrrrrr (r, D-enantiomer arginine) (21, 22) . For the synthesis of p16 MIs, the 10 sequential amino acid residue sequence 'FlDTlVVlHR', identified as the mIs of p16 by Fahraeus et al (24) , was defined as the functional core of the peptide, which is insoluble, as is the entire p16 molecule (mIs hydrophobicity, 69.2%). we therefore fused r9 to these 10 amino acids to make the conjugate less hydrophobic (hydrophobicity, 40%), thus facilitating incorporation into the cells.
Peptide transduction. For the incorporation of the peptide mixture for in vitro growth suppression, the Wr-t and r9-p16 MIs peptides were mixed in 10 µl of distilled water at room temperature for 60 min (final concentration: wr-T, 5 µmol/l; r9-p16 mIs, 8 µmol/l). The solution was then added directly to 190 µl of rpMI-1640 containing 5% fetal bovine serum to obtain the indicated final concentration. In vivo peptide delivery to solid human rCC was performed as follows: the wr-T/r9-p16 mIs peptide mix (wr-T, 50 nmol; r9-p16 mIs, 80 nmol) was injected into the hearts of mice bearing tumors that had grown to a diameter of 5 mm (tumor volume, ~150 mm
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). Control groups were done in parallel by administering 100 µl of pBs without peptide, Wr-t or p16 peptide alone dissolved in 100 µl of Pbs and injected as previously described (22) .
Flow cytometry. Cell cycle analysis was carried out using FACsCanto (bD, Franklin lakes, usA) on cells whose DNA was stained with 10 mg/ml propidium iodide 24 h after the introduction of the peptides, according to the manufacturer's staining protocol (cell cycle analysis, Genescript, Piscataway, Nj, usA). Apoptosis assays were performed using the FITCAnnexin V staining kit (mbl, Ina, japan) on peptide-treated cells followed by FACsCanto analysis.
Reverse transcription PCR. Five micrograms of total RNA was extracted from each sK-RC/575A cell line using RNaesy mini (Qiagen, Valencia, CA, usA). subsequently, cDNA was synthesized from the extracted RNA using random primers and a cDNA synthesis kit (High Capacity cDNA RT Kit, Applied biosystems, Foster City, CA usA). Reverse transcription-PCR was then carried out with Taq polymerase (Ampli-Taq Gold, Applied biosystems). Amplification conditions and primer sequences are listed in Table I . The sense/antisense primer sequences for CDK4, CDK6 and Cyclin D were as described previously (25) .
Western blotting. Cells were promptly lysed with sDs sample lysis buffer and the extracts were separated by sDs-PAGe using 12.5-15% bis-Tris gradient gels (supersepAce, wako, osaka, 6 cells of the human RCC line, sK-RC-7, was injected s.c. into the flanks of each mouse to form a solid tumor nodule. Animal experiments performed in this study were approved by the Aichi medical university subcommittee on Animal Research. All mouse procedures, euthanasia and surgery, including renal cell cancer transplantations and peptide injections, were done painlessly or under anesthesia, within the strict guidelines of the experimental Animal Facility of Aichi medical university.
Apoptosis analysis. Detection of apoptotic cells were detected in tumors harvested from mice 48 h after the peptide administration. Tumors were fixed in 10% neutral buffered formalin overnight and were then processed, paraffin embedded, sectioned and mounted onto slides. Apoptosis in the tumor sections was determined by the terminal deoxynucleotidyl transferasemediated duTP-biotin nick-end labeling (TuNel) assay method with the use of the In Situ Cell Death Detection Kit (Roche Diagnostics, Tokyo, japan) following the manufacturer's instructions.
Results
INK4 family tumor suppressor background in RCC.
we first examined the mRNA and protein expression status of p16 and several key molecules associated with the cell cycle from 10 rCC lines. Immunoblotting analysis showed that none of the 10 rCC lines expressed the p16 protein product, but expressed p27 protein, and 6 out of 10 cell lines expressed p21 protein, all renal cancer cell lines expressed the phosphorylated form of the pRb protein (Fig. 1A) . Consistent with this non-expression of the p16 molecule, multiple forms of phosphorylated prB, including ser
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, were detected in these cells, indicating prb activation along with accelerated cell proli-feration. In addition, RT-PCR analysis detected Cyclin D, CDK4 and CDK6 in RNAs from all 10 RCC lines, but not p16 (Fig. 1b) .
Growth inhibition of RCCs by the Wr-T/r9-p16 transduction
system. Based on these results, we attempted to suppress the growth of rCC cells by using the Wr-t-transported r9-p16 MIs. We introduced r9-p16 MIs into this background by mixing each RCC line with wr-T (final concentration: wr-T, 5 µmol/l; r9-p16 mIs, 8 µmol/l) and monitoring cell proliferation, starting with 4.0x10 4 cells per incubation. Administration of r9-p16 mIs alone showed some growth suppression in 7/10 cell lines. However, all tumor lines incubated with the wr-T/r9-p16 mIs mixture showed drastic suppression of cell proli-feration (Fig. 2) . At 24 h posttransduction, FACs analysis with propidium iodide staining showed that sK-RC-7 cells incubated with the wr-T/r9-p16 mIs mixture preferentially accumulated at the G0-G1 (71.3%) phase, compared with mock-treated cells (69.6%) and cells treated only with r9-p16 mIs (53.9%) (Fig. 3) . This result was similar to that obtained with cells treated with staurosporin, a G0-G1 cell cycle inhibitor (26) . because arrest in G1 phase is expected to abrogate phosphorylation of prB, we investigated the practical effect that the wr-T/r9-p16 mIs mixture would have on prB status. By 72 h post-transduction, phospholylated pRb was dramatically decreased in cells containing the wr-T/ r9-p16 MIs mixture, which is consistent with the induction of cell cycle arrest effected by the newly introduced p16 MIs (Fig. 4) . About 52% of these cells were Annexin V positive at 24 h post-transduction, suggesting that the nuclear r9-p16 MIs had triggered apoptosis (Fig. 5) .
In vivo RCC tumor suppression by the Wr-T/r9-p16 transduction system. Because of the therapeutic potential of the wr-T/r9-p16 mIs delivery system, we tested the efficacy of this system for the treatment of the human rCC line, sKrC-7, xenografts transplanted subcutaneously in KsN nude mice. when tumors grew to 5 mm, we administered the wr-T/r9-p16 mIs mixture into the mice via cardiac delivery. A clear decrease in tumor size was evident after the first ten days in the mice treated with a single dose of the wr-T/r9-p16 mIs mixture, whereas the peptide free tumors grew to twice their initial size. In addition, sustained suppression of tumor growth continued to 28 days in mice treated with three doses of the wr-T/r9-p16 mIs mixture, though tumor growth eventually resumed in mice receiving only a single dose (Fig. 6A and b) . At 48 h post-transduction, TuNel analysis showed an increase in the presence of positively stained apoptotic bodies in tumor treated with the wr-T/r9-p16 mIs mixture (Fig. 6C) , suggesting that the nuclear incorporation of the r9-p16 MIs had triggered apoptosis.
Discussion
Cancer cells grow abnormally, probably because they have escaped the cell cycle control present in normal cells. One example is cell cycle progression caused by overexpression of Cyclin D1 due to translocation or amplification of the PRAD1 gene (27) . Another example is cell cycle progression mediated by cyclin (which does not work in normal cells) due to the absence of cyclin inhibitors, such as p16
INK4a and p27 Kip1 (28) . several reports are available on the expression of molecules involved in the cell-cycle process in patients with renal cell carcinoma. Ikuerowo et al analyzed the expression of p16 INK4a in tumor samples from renal cell carcinoma using immunostaining, and observed absent or low expression of this gene in 82% of samples (29) . scharml et al performed microarray analysis and reported cyclin-dependent kinase inhibitor 2A (CDKNA2A, p16
